August 2022
Requirements changed for some commercial medical benefit drugs
Blue Cross Blue Shield of Michigan and Blue Care Network encourage proper utilization of high-cost medications that are covered under the medical benefit. As part of this effort, we maintain a comprehensive list of requirements for Blue Cross and BCN group and individual commercial members.
From March through June 2022, we added prior authorization requirements, site-of-care requirements or both for Blue Cross commercial and BCN commercial members for the following medical benefit drugs:
HCPCS code |
Brand name |
Generic name |
Q5124 |
Byooviz™ |
ranibizumab-nuna |
C9098 |
Carvykti™ |
ciltacabtagene autoleucel |
C9094 |
Enjaymo™ |
sutimlimab-jome |
For additional details, see the Blue Cross and BCN utilization management medical drug list. This list is available on the following pages of the ereferrals.bcbsm.com website:
As a reminder, an authorization approval isn’t a guarantee of payment. Health care providers need to verify eligibility and benefits for members.
Additional information
For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list. A link to this list is also available on the Blue Cross Medical Benefit Drugs page of the ereferrals.bcbsm.com website.
Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program. |